Skip to content

Observational study on the effect of the treatment of eradication of helicobacter pylori infection with voronoxan combined with high-dose amoxicillin and bismuth quadruple on intestinal flora

Observational study on the effect of the treatment of eradication of helicobacter pylori infection with voronoxan combined with high-dose amoxicillin and bismuth quadruple on intestinal flora

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084437
Enrollment
Unknown
Registered
2024-05-16
Start date
2024-05-16
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Determine Helicobacter pylori infection by C13 or C14 breath test or rapid urease test; 2. Vonolasone plus high-dose amoxicillin or Vonolasone plus metronidazole+amoxicillin+bismuth quadruple therapy was selected. 3. The age is between 25 and 55; 4. I have not participated in other research projects at present; 5. Agree to participate in this research project and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Use antibiotics or probiotics in the last 2 months; 2. Lactating or pregnant women; 3. Have serious diseases such as heart, lung, liver and kidney; 4. Personal history of digestive tract tumor, inflammatory bowel disease and colorectal cancer; 5. Patients with metabolic diseases such as diabetes and BMI greater than 30; 6. Suffering from malignant tumor or chronic diseases of other systems; 7. Patients with chronic diarrhea and recent acute pancreatitis; 8. Have an allergic history to any drug in the scheme; 9. Hp was not eradicated by the above two schemes.

Design outcomes

Primary

MeasureTime frame
Fecal flora;

Countries

China

Contacts

Public ContactLu Yingying

Shanghai General Hospital

yingying.lu1@shgh.cn+86 186 2158 3036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026